Cargando…

The GenoDiabMar Registry: A Collaborative Research Platform of Type 2 Diabetes Patients

The GenoDiabMar registry is a prospective study that aims to provide data on demographic, biochemical, and clinical changes in type 2 diabetic (T2D) patients attending real medical outpatient consultations. This registry is also used to find new biomarkers related to the micro- and macrovascular com...

Descripción completa

Detalles Bibliográficos
Autores principales: Sierra, Adriana, Otero, Sol, Rodríguez, Eva, Faura, Anna, Vera, María, Riera, Marta, Palau, Vanesa, Durán, Xavier, Costa-Garrido, Anna, Sans, Laia, Márquez, Eva, Poposki, Vladimir, Franch-Nadal, Josep, Mundet, Xavier, Oliveras, Anna, Crespo, Marta, Pascual, Julio, Barrios, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911424/
https://www.ncbi.nlm.nih.gov/pubmed/35268522
http://dx.doi.org/10.3390/jcm11051431
Descripción
Sumario:The GenoDiabMar registry is a prospective study that aims to provide data on demographic, biochemical, and clinical changes in type 2 diabetic (T2D) patients attending real medical outpatient consultations. This registry is also used to find new biomarkers related to the micro- and macrovascular complications of T2D, with a particular focus on diabetic nephropathy. With this purpose, longitudinal serum and urine samples, DNA banking, and data on 227 metabolomics profiles, 77 immunoglobulin G glycomics traits, and other emerging biomarkers were recorded in this cohort. In this study, we show a detailed longitudinal description of the clinical and analytical parameters of this registry, with a special focus on the progress of renal function and cardiovascular events. The main objective is to analyze whether there are differential risk factors for renal function deterioration between sexes, as well as to analyze cardiovascular events and mortality in this population. In total, 650 patients with a median age of 69 (14) with different grades of chronic kidney disease—G1–G2 (eGFR > 90–60 mL/min/1.73 m(2)) 50.3%, G3 (eGFR; 59–30 mL/min/1.73 m(2)) 31.4%, G4 (eGFR; 29–15 mL/min/1.73 m(2)) 10.8%, and G5 (eGFR < 15 mL/min/1.73 m(2)) 7.5%—were followed up for 4.7 (0.65) years. Regardless of albuminuria, women lost 0.93 (0.40–1.46) fewer glomerular filtration units per year than men. A total of 17% of the participants experienced rapid deterioration of renal function, 75.2% of whom were men, with differential risk factors between sexes—severe macroalbuminuria > 300 mg/g for men OR [IQ] 2.40 [1.29:4.44] and concomitant peripheral vascular disease 3.32 [1.10:9.57] for women. Overall mortality of 23% was detected (38% of which was due to cardiovascular etiology). We showed that kidney function declined faster in men, with different risk factors compared to women. Patients with T2D and kidney involvement have very high mortality and an important cardiovascular burden. This cohort is proposed as a great tool for scientific collaboration for studies, whether they are focused on T2D, or whether they are interested in comparing differential markers between diabetic and non-diabetic populations.